Halobetasol propionate lotion shows efficacy for Tx of psoriasis

October 10, 2018

(HealthDay)—Halobetasol propionate 0.01 percent lotion (BRYHALI Lotion) appears safe and effective for the treatment of moderate-to-severe plaque psoriasis, according to the results of two phase 3 trials published in the October issue of the Journal of Drugs in Dermatology.

Lawrence J. Green, M.D., from George Washington University in Washington, D.C., and colleagues randomized (2:1) 430 to receive halobetasol propionate Lotion or vehicle once daily for eight weeks, with assessments at two, four, six, and eight weeks of treatment as well as at a four-week post-treatment follow-up visit.

The researchers found that the halobetasol propionate lotion was consistently more effective than the vehicle in achieving treatment success (defined as at least a two-grade improvement from baseline in an Investigator Global Assessment score and "clear" or "almost clear" skin). At eight weeks, 36.5 percent (Study 1) and 38.4 percent (Study 2) of lotion patients achieved versus 8.1 and 12 percent of patients, respectively, receiving vehicle. There was no rebound of symptoms at the four-week post-treatment assessment. A similar number of patients in the lotion and vehicle groups reported (21.5 and 23.9 percent, respectively), and only 1.8 percent of reported adverse events were considered treatment-related.

"If approved, BRYHALI Lotion can provide physicians and their patients with a new option with a longer duration of use," a coauthor said in a statement.

Several authors disclosed financial ties to pharmaceutical companies, including Ortho Dermatologics, which manufactures halobetasol propionate and funded the study.

Explore further: Shower cream, body lotion combo improves atopic dry skin

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Shower cream, body lotion combo improves atopic dry skin

May 15, 2018
(HealthDay)—A shower cream and a body lotion with physiological lipids are effective in improving skin hydration in patients with dry skin, according to a study published online May 10 in the Journal of Cosmetic Dermatology.

TYK2 inhibitor clears psoriasis over 12 weeks

October 9, 2018
(HealthDay)—Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks, according to a phase 2 study published in ...

Fostamatinib seems effective for immune thrombocytopenia

September 5, 2018
(HealthDay)—Fostamatinib produces clinically meaningful responses in adults with immune thrombocytopenia (ITP), according a study published in the July issue of the American Journal of Hematology.

Secukinumab effective for moderate / severe scalp psoriasis

September 29, 2017
(HealthDay)—Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of ...

Single topical ivermectin head lice treatment very effective

November 2, 2012
(HealthDay)—A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day, according to a study published in the Nov. 1 issue of the New England ...

ABP 501, adalimumab biosimilar, safe and effective, for psoriasis

August 2, 2017
(HealthDay)—The biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of moderate-to-severe plaque psoriasis, according to a study published online July 28 in the British Journal of ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.